RGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RGEN is not a good buy right now for an impatient investor. The stock is technically weak (momentum still deteriorating) and is trading below a key support zone, while options positioning shows heavy put open interest (bearish/hedged stance). Despite strong revenue growth and clearly improving demand signals in the news/analyst commentary, the near-term setup still skews to further downside/volatility into the next earnings (2026-02-23). I would hold off on new buying until price stabilizes back above support (around ~154–163) and momentum stops worsening.
Price/Trend: RGEN is down -2.36% to 151.86 and is trading below S1 (153.962), approaching S2 (148.47). This indicates a breakdown of near-term support and increases the odds of a retest of the lower support zone. Momentum: MACD histogram is -1.544 and negatively expanding, confirming bearish momentum is strengthening (downtrend pressure still active). Mean-reversion signal: RSI(6) at 19.66 is deeply oversold, so a short-term bounce is possible; however, oversold can persist in strong downtrends. Levels: Pivot 162.851 is the key “reclaim” level for bulls; below it, rallies may be sold. Near-term support is ~148.47; resistance sits ~162.85 then ~171.74. Quant-style pattern read: Similar-pattern projection suggests mild-to-moderate negative drift (about -2.35% next week, -6.88% next month), aligning with the current bearish momentum.
Product catalysts: Launch of three new high-performance chromatography resins (viral vectors / gene therapy workflows), which can support mix and growth if adoption ramps.
with bearish MACD; downside risk remains toward ~148.47 if support fails.
on 2026-02-23 pre-market can be a volatility catalyst; with momentum weak, any miss/soft guide could extend the selloff.
Latest reported quarter: 2025/Q3. Growth: Revenue increased to $188.805M, +21.91% YoY, indicating solid top-line recovery. Margins: Gross margin improved to 53.24% (+4.41% YoY), a constructive sign for operating leverage potential. Bottom line: Net income fell to $14.911M (-2379.97% YoY) and EPS to $0.26 (-2700% YoY). That magnitude typically signals a difficult comp or one-time items; regardless, it highlights earnings quality/consistency as a current investor concern.
Recent trend: Analysts have been raising price targets and reiterating positive ratings.
